Physician profile
Sara Varghai
NPI 1912333121
$6,970.02
in general payments reported to CMS, 2019-2025
14 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,075 · 2020: $446 · 2021: $171 · 2022: $376 · 2023: $324 · 2024: $177 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810 · Entertainment: $91.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.98 |
| Entertainment | $91.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,027.52 | 2019-2025 | Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,433.14 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $1,219.22 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $259.39 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $145.41 | 2023-2024 | Omni Surgical System, Tearcare System |
| Kala Pharmaceuticals, INC. | $138.38 | 2021 | |
| Sun Pharmaceutical Industries INC. | $118.02 | 2023 | Cequa |
| Maculogix, INC. | $117.92 | 2020 | |
| Allergan, INC. | $111.07 | 2022 | |
| Coopervision INC. | $107.41 | 2020-2021 | |
| Optos, INC. | $91.26 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $90.00 | 2019 | |
| Rxsight INC | $78.39 | 2022 | |
| Bausch & Lomb Americas INC. | $32.89 | 2024-2025 | Infuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Varghai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.